<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534153</url>
  </required_header>
  <id_info>
    <org_study_id>20-31871</org_study_id>
    <nct_id>NCT04534153</nct_id>
  </id_info>
  <brief_title>Excipient Effect on Drug Absorption in Humans</brief_title>
  <official_title>The Effect of Sodium Lauryl Sulfate on the Oral Absorption of Fexofenadine in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if sodium lauryl sulfate (SLS), a non-drug&#xD;
      ingredient commonly added in drug products, affect absorption of drugs that are given&#xD;
      together with the ingredient. Investigators want to find out if drug absorption is different&#xD;
      in people taking the drug alone compared to people taking the drug with low and high amounts&#xD;
      of sodium lauryl sulfate at the same time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, double-blind, 3-period crossover trial. Participants&#xD;
      will be randomized to receive a Control capsule (fexofenadine single agent) under Treatment&#xD;
      Arm 1 or a Test 1 capsule (fexofenadine and 3 mg SLS) under Treatment Arm 2 or Test 2 capsule&#xD;
      (fexofenadine and 30 mg SLS) under Treatment Arm 3. Investigators will assess the effect of&#xD;
      SLS on the absorption of fexofenadine by measuring SLS and fexofenadine concentrations in&#xD;
      plasma and stool samples and determine the change in AUC (area under the curve), Cmax and&#xD;
      other pharmacokinetic parameters, between Treatment Arms 2 or 3 and Treatment Arm 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a single-center, randomized, double-blind, 3-period crossover trial. Subjects will be randomized to receive fexofenadine only under Treatment Arm 1 or fexofenadine and 3 mg SLS under Treatment Arm 2 or fexofenadine and 30 mg SLS under Treatment Arm 3.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of Fexofenadine</measure>
    <time_frame>0-48 hours</time_frame>
    <description>To determine whether SLS decreases the fexofenadine area under the curve (AUC) between Fexofenadine + 3 mg SLS or Fexofenadine + 30 mg SLS and Fexofenadine only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Fexofenadine</measure>
    <time_frame>0-48 hours</time_frame>
    <description>To determine whether SLS decreases the fexofenadine Cmax between Fexofenadine + 3 mg SLS or Fexofenadine + 30 mg SLS and Fexofenadine only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sodium lauryl sulfate plasma concentration</measure>
    <time_frame>0-48 hours</time_frame>
    <description>To determine plasma SLS concentration in order to understand the absorption of SLS in humans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fexofenadine stool amount</measure>
    <time_frame>0-48 hours</time_frame>
    <description>To determine stool amount of fexofenadine and compare between the fexofenadine only arm to the 3 mg SLS and the 30 mg SLS arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium lauryl sulfate stool amount</measure>
    <time_frame>0-48 hours</time_frame>
    <description>To determine stool amount of sodium lauryl sulfate and compare between the fexofenadine only arm to the 3 mg SLS and the 30 mg SLS arm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>The Impact of Excipients on Drug Absorption</condition>
  <arm_group>
    <arm_group_label>Fexofenadine without SLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine and 3 mg SLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine and 30 mg SLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine Hydrochloride without sodium lauryl sulfate</intervention_name>
    <description>without sodium lauryl sulfate</description>
    <arm_group_label>Fexofenadine without SLS</arm_group_label>
    <other_name>Allegra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine Hydrochloride with sodium lauryl sulfate</intervention_name>
    <description>with sodium lauryl sulfate</description>
    <arm_group_label>Fexofenadine and 3 mg SLS</arm_group_label>
    <arm_group_label>Fexofenadine and 30 mg SLS</arm_group_label>
    <other_name>Allegra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers of all ethnic groups and races.&#xD;
&#xD;
          2. Male and females between the ages of 18-64 years old, inclusive.&#xD;
&#xD;
          3. Subjects who are willing to avoid ingestion of fruit juices and citrus bioflavonoids,&#xD;
             such as grapefruit extract, hesperidin supplement and naringin supplement, for a&#xD;
             period extending from one week prior to the initiation of the study until its&#xD;
             completion.&#xD;
&#xD;
          4. Written informed consent obtained from the subject and ability for subject to comply&#xD;
             with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with extreme obesity (BMI &gt; 35).&#xD;
&#xD;
          2. Subjects who are allergic to fexofenadine or SLS.&#xD;
&#xD;
          3. Subjects who have hemoglobin level lower than 12 g/dL.&#xD;
&#xD;
          4. Subjects who are pregnant, breastfeeding, or unwilling to practice birth control&#xD;
             during participation in the study.&#xD;
&#xD;
          5. Subjects consuming types of food and supplements with the potential to interfere with&#xD;
             the study objectives as judged by the Investigator.&#xD;
&#xD;
          6. Subjects taking any drugs, especially known OATP2B1 substrates (aliskiren, atenolol,&#xD;
             celiprolol, fexofenadine, rosuvastatin and ticlopidine, etc.) except birth control&#xD;
             hormonal medications.&#xD;
&#xD;
          7. Subjects with a condition, disease, or abnormality that in the opinion of the&#xD;
             Investigator would compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          8. Subjects with any disease affecting or impairing the function of the liver, kidney or&#xD;
             heart.&#xD;
&#xD;
          9. Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal&#xD;
             surgery.&#xD;
&#xD;
         10. Subjects with known infection with HIV, Hepatitis B or Hepatitis C (as determined by&#xD;
             questionnaire, no laboratory diagnostics concerning these diseases will be performed&#xD;
             within the present study). Volunteers who are cured of past Hepatitis C infection are&#xD;
             eligible to participate with a doctor's approval letter).&#xD;
&#xD;
         11. Subjects who are smokers or have smoked in the past year and/or have smoked or&#xD;
             ingested tetrahydrocannabinol/marijuana in the past week, or who are unwilling to&#xD;
             comply throughout the study period.&#xD;
&#xD;
         12. Alcohol use on average &gt; 2 servings/day or &gt; 14 servings/wk (Serving size: 12oz&#xD;
             beer/4oz wine/2oz hard liquor) in the past week or self-reported binge drinking.&#xD;
&#xD;
         13. Participating in another research study while participating in this research study.&#xD;
&#xD;
         14. Non-English speaking.&#xD;
&#xD;
         15. Subjects with abnormal laboratory results at Screening Visit as judged by the&#xD;
             Investigator or study physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Giacomini, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen M Giacomini, Ph.D.</last_name>
    <phone>415-476-1936</phone>
    <email>kathy.giacomini@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Zou, Ph.D.</last_name>
    <phone>415-514-4363</phone>
    <email>ling.zou@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ucsf Ctsi Crc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Each participant's data will be de-identified before it is shared with others who meet specified access criteria.</ipd_description>
    <ipd_time_frame>Once after publication</ipd_time_frame>
    <ipd_access_criteria>De-identified specimens may be shared with other researchers so they can use them for, but not limited to, genomic, epigenetic, metabolomic, proteomic and transcriptomic follow-up studies.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

